Publications by authors named "Ryota Sunami"
Article Synopsis
- The study examined predictive factors for asthma exacerbation in severe asthma patients enrolled in the Okayama Severe Asthma Research Program over a one-year period.
- A total of 85 patients, mostly older adults, were analyzed, with many requiring advanced treatments according to GINA guidelines and over half treated with biologics.
- Key findings indicated that past exacerbation, low asthma control test scores, low lung function measures, and high IL-10 levels were significant predictors of future asthma exacerbation events.
Protective effects of neuropeptide Y against elastase-induced pulmonary emphysema.
Am J Physiol Lung Cell Mol Physiol
April 2022
Neuropeptide Y (NPY) is a neuropeptide widely expressed in not only the central nervous system but also immune cells and the respiratory epithelium. Patients with chronic obstructive pulmonary disease (COPD) reportedly exhibit decreased NPY expression in the airway epithelium, but the involvement of NPY in the pathophysiology of COPD has not been defined. We investigated the role of NPY in elastase-induced emphysema.
View Article and Find Full Text PDFEssential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis.
Am J Physiol Lung Cell Mol Physiol
November 2021
Article Synopsis
- Acute exacerbation of idiopathic pulmonary fibrosis (IPF) is linked to poor outcomes and is characterized by inflammation driven by neutrophils, with interleukin-23 (IL-23) playing a significant role in this inflammatory response.
- In a study using mice models, elevated levels of IL-23, along with other cytokines like IL-17A and IL-22, were found in the lungs of those experiencing acute exacerbation, and blocking IL-23 led to reduced inflammation and fibrosis.
- The findings indicate that IL-23 is crucial for the exacerbation of pulmonary fibrosis, suggesting that targeting IL-23 could offer a new therapeutic approach for patients with acute exacerbation of IPF.
A 62-year-old woman with edema and color changes in her fingers underwent computed tomography (CT); slight interstitial changes were detected in the lungs with multiple tumors in the anterior and hilar region of the liver. Based on the blood test findings, she was diagnosed with interstitial pneumonia associated with systemic sclerosis. Ultrasound-guided biopsy from the hepatic hilar lymph node revealed poorly differentiated serous adenocarcinoma cells.
View Article and Find Full Text PDFObjective: A third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is the standard treatment for patients with non-small cell lung cancer harbouring mutant EGFR. Unfortunately, these patients inevitably acquire resistance to EGFR-TKI therapies, including osimertinib. However, the mechanism associated with this resistance remains unclear.
View Article and Find Full Text PDFWe report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion.
View Article and Find Full Text PDF